NEW YORK (GenomeWeb News) — Roche plans to buy an Alnylam research facility in Germany, has licensed Alnylam’s RNAi IP, and will work with the RNAi company on drug-discovery projects, Roche said today.
 
Under the agreement, worth $331 million plus unknown milestones and royalties, Roche will acquire the Alnylam lab in Kulmbach, along with about 40 employees, once the deal is cleared by regulators in around 30 days, Roche said. Roche will use the site to create a Center of Excellence for RNAi therapeutics research.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.